SETTING: This study was performed on free living subjects attending the body composition laboratory on a monthly basis for a total of six months. SUBJECTSaDESIGN: Thirty-one abdominally obese men (30`body mass index (BMI)`40, waist-to-hip ratio (WHR)b0.95) were enrolled in a placebo-controlled randomized double-blind study, using either dexfen¯uramine (dfen) or placebo, whilst also receiving food and ®tness counselling. After a two week run-in period they were randomized to either d-fen or placebo for three months. This was followed by a further three months without medication, although food and ®tness counselling continued. METHODS: Body composition assessment included anthropometry (weight, height and abdominal circumferences), dual-energy X-ray absorptiometry (DEXA) for total body fat, and intra-abdominal fat measured via magnetic resonance imaging (MRI) at the L3aL4 level. Biochemistry included serum lipids, insulin and glucose. All measurements including blood pressure were performed at baseline, three months and six months. STATISTICAL ANALYSIS: The change within each group in the three months on medication (d-fen or placebo) was assessed by paired t-tests, whilst the difference between the groups at baseline and at three months (measured by percentage change from baseline) was assessed by unpaired t-tests. An analysis of variance was performed over the six months for the d-fen group and the placebo group separately, to determine the overall effect of three months treatment with either d-fen or placebo, three months after medication had ceased. OUTCOMES AT THREE MONTHS: At three months, BMI decreased by 75.8 AE 0.8% in the group on d-fen and by 72.7 AE 0.8% in the placebo group (P`0.01 d-fen vs placebo). There was also a signi®cant difference in the reduction of the visceral fat area between the groups (721.0 AE 4.0% in the d-fen group vs 76.7 AE 2.2% in the placebo group, P`0.01) although there was no signi®cant difference between groups with regard to reduction in subcutaneous fat area. The visceral : subcutaneous fat ratio (VaS ratio) was signi®cantly reduced between groups at three months (713.3 AE 4.9% in the d-fen group vs 70.7 AE 3.0% in the placebo group, P 0.03). At three months, the only metabolic parameters to show signi®cant difference between the two groups were total cholesterol and LDL cholesterol. Total cholesterol reduced by 712.4 AE 2.0% in the d-fen group compared with 72.3 AE 2.1% in the placebo group (P`0.01). LDL cholesterol reduced by 715.6 AE 2.6% in the d-fen group compared with 71.2 AE 2.8% in the placebo group (P`0.01). OUTCOMES AT SIX MONTHS: In the d-fen group, the reductions in BMI, abdominal circumference and % total body fat (DEXA) were sustained after three months on no medication, whereas all changes in body composition seen in the group on placebo at three months, had reverted at the three month follow-up. Both groups sustained a reduction in the insulin to glucose (IaG) ratio and systolic and diastolic blood pressure for three months after medication was ceased, while those on d-fen initially also maintained a reduction in total and LDL cholesterol.
Introduction
Reduction of weight or fat mass using dexfen¯ura-mine (d-fen) has been shown to improve metabolic indices such as hyperlipidaemia, hypertension and insulin resistance, in both obesity and diabetes mellitus. 1 ± 4 It is the visceral adipose tissue (VAT) component of total body weight, which is thought to be the major contributor to many of the manifestations of the metabolic syndrome and now with the development of direct methods of assessing VAT by either magnetic resonance imaging (MRI) or computerised tomography (CT) replacing the indirect anthropometric measures, VAT loss can be assessed. No study to date has shown VAT reduction without some accompanying reduction in subcutaneous fat (SAT) or total body fat, although studies using diets, 5, 6 exercise 7 and d-fen, 4 have signalled improved metabolic parameters associated with VAT loss.
In order to study whether`selective' or`preferential' reduction in VAT is associated with better metabolic outcome, we decided to observe the effect of lifestyle modi®cation with or without d-fen on abdominally obese men. We selected subjects without either hyperlipidaemia or diabetes and measured total body fat, visceral fat and metabolic parameters before and after the intervention.
Methods

Patients
Thirty-one healthy obese men were recruited through hospital¯yers and newspaper advertisements. Entry criteria included: age between 30±60 y, body mass index (BMI) between 30±40 kgam 2 and waist-to-hip ratio (WHR) b0.95. Subjects with known diabetes, thyroid disease or Cushing's disease, were excluded, as were smokers. Only subjects reporting an alcohol intake of`4 standard drinksad were recruited.
Forty-®ve men were initially screened and of these, two were found to have elevated 24 h levels of urinary cortisol. These men were referred to the endocrinology unit at the hospital and one was subsequently diagnosed as having Cushing's disease. Ten of the 31 men recruited had known hypertension and eight were on an anti-hypertension medications. Baseline characteristics of the two groups were similar in all of the indices assessed.
Protocol
After a two week run-in period, subjects were randomly allocated in a double blind manner to one of two groups. One group received food and ®tness counselling on a monthly basis for six months in addition to receiving d-fen for the initial three months, while the second group received food and ®tness counselling for six months with placebo given for the ®rst three months only. Amongst other parameters studied, we present here the data for BMI, percent total body fat by dual-energy X-ray absorptiometry (DEXA) and intra-abdominal fat area by abdominal MRI, which was performed at baseline, three months and six months. Biochemical parameters and blood pressure were also measured on these occasions.
The study was approved by the ethics committee at Monash Medical Centre and written consent was obtained from each subject.
Body composition
Anthropometry. Anthropometry including body weight to the nearest 0.01 kg and height to the nearest 1 mm was measured by the same experienced nursing sister. BMI (kgam 2 ) was calculated and abdominal and gluteal girths were measured to the nearest 1 mm with a plastic tape using bony land marks as described by the World Health Organization (WHO) criteria.
Abdominal : gluteal ratio (AGR) was calculated by dividing the abdominal circumference by the gluteal circumference.
DEXA. Total body fat was assessed by a Lunar DPX (Lunar Radiation Corp, Madison, Wisconson) using software version 3.6z and expressed as % body weight.
MRI. Single scans were taken at the L3aL4 level using a General Electric Medical Systems (Milwalkee, USA) Signa Advantage machine operating at 1.5 Tesla using software system 5.4. Scans were analysed by a single experienced operator and the area of both subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) (in cm 2 ) was measured using a technique previously described. 4 The VAT : SAT (VaS) ratio was determined.
Biochemistry
Fasting serum glucose and insulin levels were taken by standard biochemical means and the insulin to glucose ratio (IaG ratio) was used to assess insulin sensitivity. Other metabolic indices including fasting lipids and HDL cholesterol were also measured using standard techniques. LDL cholesterol was calculated using the Friedewald formula.
Blood pressure
Systolic and diastolic blood pressures were taken in the supine position after ®ve minutes rest, using a large cuff, if necessary.
Statistics
Data was analysed using the statistical program Graphpad Prism Version 2.00 (Graphical Software, San Diego, USA). Baseline data together with changes over the ®rst three months (described as percentage change from baseline) between the two groups, were compared using unpaired t-tests. Changes within the groups during the initial three month treatment with either d-fen or placebo were assessed using paired ttests. Analysis of variance was performed at 0±3±6 months to assess the overall effect of the intervention (d-fen or placebo for three months followed by three months continued food and ®tness counselling). All results are expressed as mean AE standard error of the mean (s.e.m.). Two sided P values`0.05 were considered to be signi®cant.
Results
Thirty of the 31 men recruited completed the study. One subject stopped after only two weeks because of poor compliance. One subject was unable to have MRI studies performed, due to previously undiagnosed claustrophobia, while three of the remaining 87 MRI studies could not be analysed due to technical dif®culties associated with the scanning procedure. Side effects noted in both groups included dry-mouth, lethargy and increased stool frequency, but drug withdrawal was not necessary.
After three months
Body composition. At baseline, by unpaired t-test, body composition parameters were not different between the two groups. Changes in body composition over the ®rst three months are noted in Table 1 .
In the group treated initially with placebo, there was a reduction in BMI, abdominal circumference and MRI visceral fat area, but not in MRI subcutaneous fat area. There was no statistical reduction in AGR, % total body fat nor in the VaS ratio.
In the group on d-fen, BMI, AGR and abdominal circumference all decreased signi®cantly as did % total body fat. The MRI visceral fat area and MRI subcutaneous fat area both reduced while the reduction in the VaS ratio indicates a preferential reduction in visceral fat.
Percentage reduction in body composition parameters over the ®rst three months between the placebo and d-fen groups are shown in Table 2 .
There was a signi®cant difference between the two groups in the percentage reduction of BMI, MRI visceral fat area and VaS ratio over this time.
Metabolic parameters The data related to changes in metabolic parameters are shown in Table 1B . At baseline, by unpaired t-test, there was no statistical difference between the two groups. In both groups, Table 4 .
There was a signi®cant difference between the two groups in the percentage reduction of total and LDL cholesterol over this time.
Overall effect of intervention
Body composition. The overall effect of intervention (d-fen or placebo for the initial three months only, with continued food and ®tness counselling for a further three months) as assessed by ANOVA, is also shown in Table 1 . Changes between the groups cannot be compared statistically after the ®rst three months, as the intervention altered during this time.
In the placebo group, the overall effect of intervention was not signi®cant with respect to any of the body composition parameters studied, whereas for the group on d-fen, there was a sustained reduction in BMI, abdominal circumference and DEXA % total body fat. The reduction in visceral fat and VaS ratio was no longer signi®cant once treatment with d-fen ceased.
Metabolic parameters. This data is shown in Table  2 . In both groups there was a statistically signi®cant persistent effect on systolic and diastolic BP and IaG ratio. Additionally in the d-fen group, the overall effect of intervention showed a sustained reduction in total and LDL cholesterol.
Discussion
Over the past few years, many attempts have been made to determine the effect of dietary restriction, with or without exercise, on body fat distribution, with particular emphasis on visceral fat changes, as seen on either MRI or CT. Gray et al 9 using MRI, reported a signi®cant reduction in both subcutaneous and visceral fat area in obese women treated for 10 weeks with a very low calorie diet (VLCD). In 1991, Fujioka et al, 10 using CT, showed a signi®cant reduction in visceral fat volume and VaS ratio predominantly in women with a high initial VaS ratio (b0.4) after treatment with a low calorie diet (800 Kad) for eight weeks, whereas Ross and Rissanen 11 found that moderate energy restriction together with either resistance or aerobic exercise, induced signi®cant reduction in SAT, with a preferential loss of VAT.
Pharmacological intervention has also been trialled by Visser et al, 12 reporting reduced BMI and subcutaneous fat area using MRI in overweight men treated with¯uoxetine and dietary counselling, with no selective or preferential reduction in visceral fat area. We have previously shown a preferential reduction in VAT in an open, uncontrolled trial using dexfen¯uramine to Reduction of visceral adipose tissue SJ Marks et al treat overweight men with non-insulin dependent diabetes mellitus (NIDDM). 4 A consistent theme in these ®ndings, is that subjects with the largest amounts of VAT are likely to lose the most. As VAT is known to be higher in men and with increasing age, it is not surprising that different studies using different study cohorts show varying results.
Few studies have used d-fen together with food and ®tness counselling in a placebo-control, double blind manner, in an attempt to differentiate the bene®ts of d-fen from the effect of ongoing food and ®tness counselling. We report signi®cant improvement in the BMI, abdominal circumference and visceral fat area, in subjects given food and ®tness counselling plus placebo over the initial three months of the study. However the VaS ratio did not alter in these men. The overall effect of the six months intervention (three months on placebo with three months follow-up) was not signi®cant with regard to body composition parameters, although metabolic improvements persisted.
These ®ndings are in contrast to those of Ross and Rissanen, 11 who did ®nd a reduction in VaS ratio with weight loss. However they studied women and energy restriction was used, whereas we gave advice to limit fat intake, without prescribing an energy intake target. Additionally they used aerobic or resistance training, whereas we advised regular walking. The difference in the ®ndings with respect to VAT may be explained on this basis.
It may be that men and women respond differently with respect to VAT or VaS ratio when food and lifestyle are changed. There may also be differences between ethnic groups as suggested by a South African study of women from two ethnic groups. 13 In the study described here, the group given dexfen¯uramine for the ®rst three months, together with food and ®tness counselling, showed signi®cant improvement in BMI, waist circumference and visceral fat area, over the initial three months in addition to a reduced VaS ratio. The effect of the d-fen for the initial three months and lifestyle counselling over the total six months, was to sustain some of these improvements.
The greater reduction in VAT seen in the group on d-fen is no doubt part of the greater reduction in % total body fat, which was signi®cant after three months on d-fen and remained signi®cant for three months after d-fen ceased. However, in the d-fen subjects, an increase in men VAT was noted during the washout phase, whilst mean BMI and % total body fat was still reducing. In the group given placebo initially, the mean VAT continued to decrease throughout the wash-out period paralleling the continued but non-signi®cant reduction in % total body fat. This further suggests a preferential action of d-fen on visceral fat as evidenced by the signi®cant reduction in VaS ratio seen only in the d-fen group.
With regard to metabolic parameters, food and ®tness counselling without active pharmacological intervention was bene®cial in achieving reduction in systolic and diastolic BP, as well as the IaG ratio. This is similar to the study of Pfohl et al, 14 who found a signi®cant reduction in systolic BP, associated with signi®cant weight loss in the placebo group of a 12 months study using d-fen, despite no other signi®cant changes in metabolic parameters. In the current study, these bene®ts were sustained over the six month period and were detectable, despite no signi®cant sustained reduction in either BMI or % body fat.
The group given d-fen, in addition to food and ®tness counselling, also showed the improved systolic and diastolic BP and IaG ratio. They additionally showed a reduction in total cholesterol and LDL cholesterol which was sustained over the six months period. The improvement in total cholesterol and LDL cholesterol in the d-fen group suggests that this was related to the preferential reduction in VAT. Improvements in BP and insulin resistance seen in the metabolic syndrome, may be dependent on loss of both total body fat and visceral fat, but changes in lipids may require a preferential and signi®cant loss of visceral fat.
While it is possible that some of the observed effects are due to a direct serotoninergic action of dfen on visceral fat, the recent world-wide withdrawal of this agent suggests that it is unlikely that these possible mechanisms will be elucidated. The results from the small cohort in the present study, over a limited period of time, suggest that it is possible to achieve a preferential reduction in VAT (as evidenced by a reduced VaS ratio). If long term reduction of visceral fat by other means can be achieved, these results have wider implications for the management of obesity and its metabolic complications.
